Search

Your search keyword '"Suh, D.J."' showing total 42 results
Start Over Author "Suh, D.J."
42 results on '"Suh, D.J."'

1. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion

Author

Lee, H.C., Suh, D.J., Ryu, S.H., Kim, H., Shin, J.W., Lim, Y.-S., Chung, Y.-H., and Lee, Y.S.

Subjects
DNA -- Genetic aspects -- Analysis -- Research -- Health aspects -- Physiological aspects, Medical virology -- Research -- Analysis -- Physiological aspects -- Health aspects, Colorectal diseases -- Research -- Causes of -- Health aspects -- Care and treatment -- Genetic aspects -- Drug therapy, Serum -- Physiological aspects -- Health aspects -- Analysis -- Research, Lamivudine -- Physiological aspects -- Dosage and administration -- Research, Patients -- Health aspects -- Care and treatment -- Genetic aspects -- Drug therapy -- Physiological aspects -- Research -- Analysis, Antigens -- Physiological aspects -- Genetic aspects -- Analysis -- Research -- Health aspects, Hepatitis B -- Health aspects -- Care and treatment -- Genetic aspects -- Drug therapy -- Research, Polymerase chain reaction -- Analysis -- Physiological aspects -- Research -- Health aspects -- Genetic aspects, Gastrointestinal diseases -- Research -- Causes of -- Health aspects -- Care and treatment -- Genetic aspects -- Drug therapy, Health, Drug therapy, Care and treatment, Physiological aspects, Analysis, Genetic aspects, Research, Dosage and administration, Health aspects, Causes of
Abstract

Gut 2003;52:1779-1783 Background and aims: Lamivudine induces favourable virological and biochemical responses but post-treatment relapses are frequent, even in patients with hepatitis B e antigen (HBeAg) loss or seroconversion. The [...]

Published
2003

2. Durability of HbeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. (Hepatitis)

Author

Nunen, A.B. van, Hansen, B.E., Suh, D.J., Lohr, H.F., Chemello, L., Fontaine, H., Heathcote, J., Song, B.C., Janssen, H.L.A., Man, R.A. de, and Schalm, S.W.

Subjects
Interferon -- Evaluation, Lamivudine -- Evaluation, Hepatitis B -- Drug therapy, Health, Drug therapy, Evaluation
Abstract

Background and aims: Interferon (IFN) induced hepatitis B e antigen (HBeAg) seroconversion is durable in 80-90% of chronic hepatitis B patients. Preliminary reports on the durability of HBeAg seroconversion following [...]

Published
2003

11. O128 SURGICAL RESECTION VERSUS RADIOFREQUENCY ABLATION IN THE TREATMENT OF PATIENTS WITH SOLITARY HEPATOCELLULAR CARCINOMA WITHOUT PORTAL HYPERTENSION: A 10-YEAR OUTCOME STUDY

Author

Kim, G.-A., primary, Shim, J.H., additional, Kim, S.Y., additional, Won, H.J., additional, Shin, Y.M., additional, Kim, P.N., additional, Lee, Y.-J., additional, Lee, S.-G., additional, Lee, D., additional, Kim, K.M., additional, Lim, Y.-S., additional, Lee, H.C., additional, Chung, Y.-H., additional, and Suh, D.J., additional

Published
2014
Full Text
View/download PDF

12. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.

Author

Young K., Sood A., Suh D.J., Wallace C., Negro F., Sievert W., Altraif I., Razavi H.A., Abdo A., Ahmed E.A., Alomair A., Amarapurkar D., Chen C.-H., Dou X., El Khayat H., elShazly M., Esmat G., Guan R., Han K.-H., Koike K., Largen A., Mccaughan G., Mogawer S., Monis A., Nawaz A., Piratvisuth T., Sanai F.M., Sharara A.I., Sibbel S., Young K., Sood A., Suh D.J., Wallace C., Negro F., Sievert W., Altraif I., Razavi H.A., Abdo A., Ahmed E.A., Alomair A., Amarapurkar D., Chen C.-H., Dou X., El Khayat H., elShazly M., Esmat G., Guan R., Han K.-H., Koike K., Largen A., Mccaughan G., Mogawer S., Monis A., Nawaz A., Piratvisuth T., Sanai F.M., Sharara A.I., and Sibbel S.

Abstract

Background: The hepatitis C pandemic has been systematically studied and characterized in North America and Europe, but this important public health problem has not received equivalent attention in other regions. Aim(s): The objective of this systematic review was to characterize hepatitis C virus (HCV) epidemiology in selected countries of Asia, Australia and Egypt, i.e. in a geographical area inhabited by over 40% of the global population. Methodology: Data references were identified through indexed journals and non-indexed sources. In this work, 7770 articles were reviewed and 690 were selected based on their relevance. Result(s): We estimated that 49.3-64.0 million adults in Asia, Australia and Egypt are anti-HCV positive. China alone has more HCV infections than all of Europe or the Americas. While most countries had prevalence rates from 1 to 2% we documented several with relatively high prevalence rates, including Egypt (15%), Pakistan (4.7%) and Taiwan (4.4%). Nosocomial infection, blood transfusion (before screening) and injection drug use were identified as common risk factors in the region. Genotype 1 was common in Australia, China, Taiwan and other countries in North Asia, while genotype 6 was found in Vietnam and other Southeast Asian countries. In India and Pakistan genotype 3 was predominant, while genotype 4 was found in Middle Eastern countries such as Egypt, Saudi Arabia and Syria. Conclusion(s): We recommend implementation of surveillance systems to guide effective public health policy that may lead to the eventual curtailment of the spread of this pandemic infection. © 2011 John Wiley & Sons A/S.

Published
2012

17. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

Author

Nunen, A.B. van, Schalm, S.W. (Solko), Hansen, B.E. (Bettina), Suh, D.J., Lohr, H.F., Chemello, L. (Liliana), Fontaine, H., Heathcote, J., Song, B.C., Janssen, H.L.A. (Harry), Man, R.A. (Robert) de, Nunen, A.B. van, Schalm, S.W. (Solko), Hansen, B.E. (Bettina), Suh, D.J., Lohr, H.F., Chemello, L. (Liliana), Fontaine, H., Heathcote, J., Song, B.C., Janssen, H.L.A. (Harry), and Man, R.A. (Robert) de

Abstract

Background and aims: Interferon (IFN) induced hepatitis B e antigen (HBeAg) seroconversion is durable in 80-90% of chronic hepatitis B patients. Preliminary reports on the durability of HBeAg seroconversion following lamivudine are contradictory. We investigated the durability of response following IFN, lamivudine, or IFN-lamivudine combination therapy in a meta-analysis of individual patient data. PATIENTS AND METHODS: Twenty four centres included 130 patients in total with an HBeAg seroconversion (HBeAg negative, antibodies to hepatitis B e antigen positive) at the end of antiviral therapy: 59 with lamivudine, 49 with interferon, and 22 with combination therapy. Relapse was defined as confirmed reappearance of HBeAg. RESULTS: The three year cumulative HBeAg relapse rate by the Kaplan-Meier method was 54% for lamivudine, 32% for IFN, and 23% for combination therapy (p=0.01). Cox regression analysis identified pretreatment hepatitis B virus (HBV) DNA, alanine aminotransferase (ALT), sex, and therapy as independent predictive factors of post-treatment relapse; Asian race, previous therapy, centre, and type of study were not predictive of relapse. The relative HBeAg relapse risk of lamivudine compared with IFN therapy was 4.6 and that of combination therapy to IFN therapy 0.7 (p(overall)=0.01). CONCLUSIONS: The durability of HBeAg seroconversion following lamivudine treatment was significantly lower than that following IFN or IFN-lamivudine combination therapy. The risk of relapse after HBeAg seroconversion was also related to pretreatment levels of serum ALT and HBV DNA, but independent of Asian race.

Published
2003

22. 691 EFFESTS OF RESPONSE TO INTERFERON THERAPY ON THE PROGRESSION TO DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIC B

Author

Jang, M.K., primary, Chung, Y.-H., additional, Yu, E., additional, Shin, H.D., additional, Lee, S.H., additional, Lee, D., additional, Kim, S.E., additional, Lee, Y.-S., additional, Kim, S.H., additional, Yang, S.H., additional, Kim, K.M., additional, Lim, Y.S., additional, Lee, H.C., additional, Lee, Y.S., additional, and Suh, D.J., additional

Published
2008
Full Text
View/download PDF

31. Upregulation of insulin-like growth factor II may be associated with metastasis of hepatocellular carcinoma following transarterial chemoembolization

Author

Song, B.-C., primary, Chung, Y.-H., additional, Park, M.I., additional, Yang, S.H., additional, Kim, J.A., additional, Hong, I.R., additional, Choi, W.B., additional, Lee, S.S., additional, Jung, S.A., additional, Yoon, H.K., additional, Sung, K.B., additional, Lee, Y.S., additional, and Suh, D.J., additional

Published
2000
Full Text
View/download PDF

33. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretretment serum hepatitis B virus DNA and alanine aminotransferase.

Author

van Nunen, A.B., Hansen, B.E., Suh, D.J., Löhr, H.F., Chemello, L., Fontaine, H., Heathcote, J., Song, B.C., Janssen, H.L.A., de man, R.A., and Schalm, S.W.

Subjects
INTERFERONS, HEPATITIS B, ANTIGENS
Abstract

Background and aims: Interferon (IFN) induced hepatitis B e antigen (HBeAg) seroconversion is durable in 80-90% of chronic hepatitis B patients. Preliminary reports on the durability of HBeAg seroconversion following lamivudine are contradictory. We investigated the durability of response following IFN, lamivudine, or IFN-lamivudine combination therapy in a meta-analysis of individual patient data. Patients and methods: Twenty four centres included 130 patients in total with an HBeAg seroconversion (HBeAg negative, antibodies to hepatitis B e antigen positive) at the end of antiviral therapy: 59 with lamivudine, 49 with interferon, and 22 with combination therapy. Relapse was defined as confirmed reappearance of HBeAg. Results: The three year cumulative HBeAg relapse rate by the Kaplan-Meier method was 54% for lamivudine, 32% for IFN, and 23% for combination therapy (p=0.01). Cox regression analysis identified pretreatment hepatitis B virus (HBV) DNA, alanine aminotransferase (ALT), sex, and therapy as independent predictive factors of post-treatment relapse; Asian race, previous therapy, centre, and type of study were not predictive of relapse. The relative HBeAg relapse risk of lamivudine compared with IFN therapy was 4.6 and that of combination therapy to IFN therapy 0.7 (p[sub overall]=0.01). Conclusions: The durability of HBeAg seroconversion following lamivudine treatment was significantly lower than that following IFN or IFN-lamivudine combination therapy. The risk of relapse after HBeAg seroconversion was also related to pretreatment levels of serum ALT and HBV DNA, but independent of Asian race. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

34. Usefulness of cholangioscopy in patients with focal stricture of the intrahepatic duct unrelated to intrahepatic stones

Author

Seo, D.W., Kim, M.H., Lee, S.K., Myung, S.J., Kang, G.H., Ha, H.K., Suh, D.J., and Min, Y.I.

Abstract

Background: Intrahepatic duct strictures are usually caused by intrahepatic duct stones and cholangitis. However, focal strictures of the intrahepatic duct unrelated to intrahepatic stones often pose diagnostic problems. This study was undertaken to prospectively evaluate the usefulness of percutaneous transhepatic cholangioscopy in patients with focal intrahepatic duct stricture and no evidence of a stone. Methods: Seventeen patients with focal strictures of the intrahepatic duct without any evidence of a stone were included. Percutaneous transhepatic cholangioscopic examination including procurement of biopsy specimens was performed after percutaneous transhepatic biliary drainage. Results: A histopathologic diagnosis was obtained in all patients (9 adenocarcinomas, 1 squamous cell carcinoma, 2 hepatocellular carcinomas, 2 adenomas, and 3 benign strictures). Of the 9 patients with bile duct adenocarcinoma, 8 underwent surgery and a curative resection was possible in 7 patients (88%). Five patients (63%) had early-stage bile duct cancer in which cancer invasion was limited to the mucosa or fibromuscular layer and there was no evidence of lymph node metastasis. Conclusions: Percutaneous transhepatic cholangioscopy in patients with focal stricture of the intrahepatic duct unrelated to choledocholithiasis is useful for diagnosis including the detection of early bile duct cancer. (Gastrointest Endosc 1999;49:204-9.)

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results